Novartis strikes against four more Indian Galvus copiers

Pre-emptive intellectual property rights-related legal action appears to be on the uptick in India with Novartis now moving the Delhi High Court against four more Indian firms alleging infringement of its patent concerning the DPP-4 inhibitor for diabetes, vildagliptin.